ArticleMaterials today. Bio2025
Dual-organelle targeted photosensitizer with AIE characteristics for triple-negative breast cancer photodynamic therapy via apoptosis and immunogenic cell death.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intrinsic AIE drug nanocrystals enable imaging-guided orchitis theranostics.Materials today. Bio · 2026Article
- A multi-level charged micelle-based microneedle transdermal system for immunosuppressive tumor microenvironment regulation and synergistic therapy.Materials today. Bio · 2026Article
- Acceptor Engineering-Mediated Charge-Transfer Control: A Hierarchical Framework for Predictive Design of High-Performance Type I AIE Photosensitizers.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- A novel photosensitizer berberine derivative B12 induces apoptosis and suppresses HIF-1α expression in colorectal cancer cells via mitochondria-to-nucleus sequential-targeting.Acta pharmacologica Sinica · 2026Article
- Breaking the siege of hypoxia and lactate: carrier-free flexible dual-enzyme protein vesicle to ignite photodynamic-immune storm in head and neck squamous cell carcinoma.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly malignant breast cancer with a high metastasis rate, weak targeted therapy effect, and short patient survival period. Current treatments have significant limitations, highlighting an urgent need for novel therapies to alleviate patient suffering. Photodynamic therapy (PDT) has emerged as a promising antitumor strategy by inducing apoptosis and immune responses through the release of reactive oxygen species (ROS). However, conventional photosensitizers (PSs) face issues such as high cytotoxicity and aggregation-caused quenching (ACQ), limiting their clinical applicability. To address these challenges, we developed a novel dual-targeting, bimolecular pathway using an advanced photosensitizer, 2TPA-PIMe, designed based on aggregation-induced emission (AIE). The rationally designed 2TPA-PIMe, incorporating alkylated phosphindole as the core, exhibits AIE properties and efficient ROS generation via both type I and type II pathways, potentially enhancing PDT effectiveness
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.